Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PALLADIUM: Rapid Drug Desensitization to Palynziq in Adults With PKU
NCT06780332Phase 4Completed
- Sponsor
- BioMarin Pharmaceutical
- Start
- Feb 2025
- Primary completion
- Aug 2026
- Modality
- PEGylated Peptides, Replacement Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of pegvaliase in phenylketonuria (PKU), sponsored by BioMarin Pharmaceutical. Started Feb 2025; status: completed.
02
Drugs
pegvaliase
03
Conditions
phenylketonuria (PKU)
Beyond the preview
Go deeper on NCT06780332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06780332.